The future outlook on allergen immunotherapy in children: 2018 and beyond
Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | Italian Journal of Pediatrics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13052-018-0519-4 |
id |
doaj-31b3779a8f99474f93542267e92cbfe0 |
---|---|
record_format |
Article |
spelling |
doaj-31b3779a8f99474f93542267e92cbfe02020-11-25T01:11:58ZengBMCItalian Journal of Pediatrics1824-72882018-07-014411910.1186/s13052-018-0519-4The future outlook on allergen immunotherapy in children: 2018 and beyondStefania Arasi0Giovanni Corsello1Alberto Villani2Giovanni Battista Pajno3Allergy Unit- Department of Pediatrics, University of MessinaDepartment of Maternal and Child Health, University of PalermoPediatric and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCSAllergy Unit- Department of Pediatrics, University of MessinaAbstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT might be a strategy to prevent the development of a new sensitization or of a (new) allergic disease. However, there are still some methodological criticisms, such as: a) the regimen of administration and the amount of the maintenance dose are both largely variable; b) the protocols of administration are not standardized; c) the description and classification of side effects is variable among studies and needs to be standardized; d) quality of life and evaluation of health economics are overall missing. All these aspects make difficult to compare each study with another. In addition, the content of major allergen(s) remains largely variable among manufacturers and the availability of AIT products differences among countries. The interest and the attention to AIT treatment are currently fervent and increasing. Well-designed studies are awaited in the near future in order to overcome the current gaps in the evidence and furtherly promote implementation strategies.http://link.springer.com/article/10.1186/s13052-018-0519-4Allergen-specific immunotherapyAllergic rhinitisAllergyChildrenFood allergyIgE-mediated allergic diseases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefania Arasi Giovanni Corsello Alberto Villani Giovanni Battista Pajno |
spellingShingle |
Stefania Arasi Giovanni Corsello Alberto Villani Giovanni Battista Pajno The future outlook on allergen immunotherapy in children: 2018 and beyond Italian Journal of Pediatrics Allergen-specific immunotherapy Allergic rhinitis Allergy Children Food allergy IgE-mediated allergic diseases |
author_facet |
Stefania Arasi Giovanni Corsello Alberto Villani Giovanni Battista Pajno |
author_sort |
Stefania Arasi |
title |
The future outlook on allergen immunotherapy in children: 2018 and beyond |
title_short |
The future outlook on allergen immunotherapy in children: 2018 and beyond |
title_full |
The future outlook on allergen immunotherapy in children: 2018 and beyond |
title_fullStr |
The future outlook on allergen immunotherapy in children: 2018 and beyond |
title_full_unstemmed |
The future outlook on allergen immunotherapy in children: 2018 and beyond |
title_sort |
future outlook on allergen immunotherapy in children: 2018 and beyond |
publisher |
BMC |
series |
Italian Journal of Pediatrics |
issn |
1824-7288 |
publishDate |
2018-07-01 |
description |
Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT might be a strategy to prevent the development of a new sensitization or of a (new) allergic disease. However, there are still some methodological criticisms, such as: a) the regimen of administration and the amount of the maintenance dose are both largely variable; b) the protocols of administration are not standardized; c) the description and classification of side effects is variable among studies and needs to be standardized; d) quality of life and evaluation of health economics are overall missing. All these aspects make difficult to compare each study with another. In addition, the content of major allergen(s) remains largely variable among manufacturers and the availability of AIT products differences among countries. The interest and the attention to AIT treatment are currently fervent and increasing. Well-designed studies are awaited in the near future in order to overcome the current gaps in the evidence and furtherly promote implementation strategies. |
topic |
Allergen-specific immunotherapy Allergic rhinitis Allergy Children Food allergy IgE-mediated allergic diseases |
url |
http://link.springer.com/article/10.1186/s13052-018-0519-4 |
work_keys_str_mv |
AT stefaniaarasi thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond AT giovannicorsello thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond AT albertovillani thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond AT giovannibattistapajno thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond AT stefaniaarasi futureoutlookonallergenimmunotherapyinchildren2018andbeyond AT giovannicorsello futureoutlookonallergenimmunotherapyinchildren2018andbeyond AT albertovillani futureoutlookonallergenimmunotherapyinchildren2018andbeyond AT giovannibattistapajno futureoutlookonallergenimmunotherapyinchildren2018andbeyond |
_version_ |
1725168407882498048 |